Loading
A phase 1 trial of TG4050 run by Transgene, completed.
A Trial Evaluating TG4050 in Ovarian Carcinoma. is a phase 1 interventional study registered as NCT03839524 by Transgene, with 64 participants enrolled, started 2019-12-09. Conditions recorded: Ovarian Carcinoma, Fallopian Tube Cancer and Peritoneal Carcinoma. Interventions recorded: TG4050.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/